@abangelabs.bsky.socialTop-ranked doesn’t mean decision-ready: why transfusion-threshold evidence in acute brain injury still needs an audit. https://www.mattheneus.com/editorial/acute-brain-injury-transfusion-threshold-bayesian-nma-evidence-audit-2026-10-12 #HTA #NMA #EvidenceSynthesis
@worldebhcday.bsky.socialRead the #WorldEBHCDay blog by Hailey Wills, Evidence Synthesis Coordinator at the Maritime SPOR SUPPORT Unit, who discusses the importance of having humans at the centre of comprehensive searches for #EvidenceSynthesis projects when using #AI tools.
Read blog: https://ow.ly/OQOi50ZVcmK
@abangelabs.bsky.socialWhy did Germany find aficamten’s added benefit unproven against mavacamten? Endpoint choice and indirect-comparison limits matter. https://www.mattheneus.com/editorial/iqwig-aficamten-obstructive-hcm-mavacamten-endpoint-itc-nonproof-2026-08-27 #HTA #MAIC #EvidenceSynthesis
@abangelabs.bsky.socialElahere’s direct survival evidence still leaves adjusted-comparison uncertainty where decision-makers need clarity. https://www.mattheneus.com/editorial/smc-elahere-mirvetuximab-mirasol-maic-survival-model-2026-10-12 #HTA #MAIC #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialIn type 3 von Willebrand disease, bleeding-rate assumptions can decide whether prophylaxis looks cost-saving. https://www.mattheneus.com/editorial/type-3-von-willebrand-prophylaxis-cost-saving-bleeding-rate-assumptions-2026-10-13 #HTA #HealthEconomics #EvidenceSynthesis
@cochrane.orgA new Cochrane review finds that existing evidence is too uncertain to determine whether medical cannabis improves sleep or daytime functioning in people with insomnia.
@abangelabs.bsky.socialMedical cannabis may help insomnia—but Cochrane says evidence across nine studies remains uncertain. https://www.mattheneus.com/editorial/cochrane-medical-cannabis-insomnia-nine-studies-low-certainty-2026-10-13 #HTA #EvidenceSynthesis #RWE
@abangelabs.bsky.socialHearing-intervention value cases can miss costs that change the economic story. https://www.mattheneus.com/editorial/hearing-intervention-economic-model-missing-costs-2026-10-12 #HTA #HealthEconomics #EvidenceSynthesis
@abangelabs.bsky.socialSMC accepts obinutuzumab for lupus nephritis—but comparator uncertainty remains in the evidence base. https://www.mattheneus.com/editorial/smc-gazyvaro-obinutuzumab-lupus-nephritis-regency-nma-flare-model-2026-10-12 #HTA #NMA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialA joint neurology guideline maps adult migraine prevention across 217 trials—and highlights the active-comparison evidence gap. https://www.mattheneus.com/editorial/aan-ahs-adult-migraine-prevention-guideline-217-trials-active-comparison-gap-2026-10-13 #HTA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialCost-effectiveness evidence doesn’t carry a passport: insulin value claims can shift sharply across countries. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/type-1-diabetes-insulin-cost-effectiveness-transferability-bias-audit-2026-10-12
@abangelabs.bsky.socialSMC accepted vutrisiran for ATTR-CM despite uncertainty around its tafamidis comparison—what evidence means for HTA decisions. https://www.mattheneus.com/editorial/smc-vutrisiran-amvuttra-attr-cm-heliosb-tafamidis-comparator-uncertainty-2026-10-12 #HTA #EvidenceSynthesis #Pharma
@abangelabs.bsky.socialTreatment rankings after stroke can shift by outcome—and wide prediction intervals temper confidence. #HTA #NMA #EvidenceSynthesis https://www.mattheneus.com/editorial/frontiers-post-stroke-shoulder-hand-syndrome-rehabilitation-network-prediction-intervals-2026-09-23
@abangelabs.bsky.socialTreatment packages can rank well in an NMA while hiding which component drives outcomes. https://www.mattheneus.com/editorial/pubmed-robot-assisted-prostatectomy-component-identifiability-network-meta-analysis-2026-10-12 #HTA #NMA #EvidenceSynthesis
@nessieevidence.bsky.socialWe have started work on our latest #NESSIE project investigating non-cancer health conditions in firefighters. Follow link in bio to read our blog on why this #evidencesynthesis is important. #bestevidence #evidencebased #EvidenceBasedPractice #evidencedbasedresearch
@abangelabs.bsky.socialA guided-growth review quantifies correction and follow-up outcomes for paediatric genu valgum. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/sicot-genu-valgum-tension-band-plate-follow-up-correction-2026-10-08
@abangelabs.bsky.socialResistance training ranks highest for cognition across AD, Parkinson’s and MCI, with low-certainty evidence.
https://www.mattheneus.com/editorial/frontiers-cognitive-exercise-network-alzheimer-parkinson-mci-low-certainty-2026-10-10
#HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialWhich therapy leads in kidney protection? A Bayesian network analysis compares SGLT2 inhibitors, semaglutide and finerenone. https://www.mattheneus.com/editorial/frontiers-diabetic-kidney-disease-sglt2-semaglutide-finerenone-bayesian-network-2026-10-09 #HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialPregnancy signals can outrank live-birth evidence in chronic endometritis. See why endpoint hierarchy matters in network meta-analysis. https://www.mattheneus.com/editorial/pubmed-chronic-endometritis-nma-live-birth-endpoint-hierarchy-2026-10-08 #HTA #NMA #EvidenceSynthesis
@abangelabs.bsky.socialCollagenopathy evidence supports phenotype-specific preterm birth risk assessment. https://www.mattheneus.com/editorial/acta-collagenopathies-marfan-ehlers-danlos-spontaneous-preterm-birth-2026-10-09 #HTA #EvidenceSynthesis #RWE